Saudi Arabia: These 2 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Saudi Arabia
Generic Entry Dates in Other Countries
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
Summary: Saudi Arabia: These 2 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
| Tradename | Ingredient | Estimated Entry Opportunity Date |
|---|---|---|
| CORLANOR | ivabradine | 2025-02-28 |
| CORLANOR | ivabradine hydrochloride | 2025-02-28 |
| >Tradename | >Ingredient | >Estimated Entry Opportunity Date |
Details: Saudi Arabia: These 2 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
When can CORLANOR (ivabradine) generic drug versions launch?
Generic name: ivabradine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2025
Generic Entry Controlled by: Saudi Arabia Patent 6,270,040
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.
When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?
Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2025
Generic Entry Controlled by: Saudi Arabia Patent 6,270,038
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
